Skip to main content

Will COVID-19 be the tipping point for primary HPV self-sampling?

0Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Self-sampling is poised to be a disruptor for cervical screening. So far, cancer screening has been a causality of COVID-19; however, the opposite may transpire for self-sampling. Self-sampling enables socially distanced cervical screening with an outreach that extends to underserved populations. As evidence mounts that self-sampling is noninferior to clinician-taken samples, the focus for self-sampling is now as a primary screening option for all women. Now, we have evidence from a modeling study (using Australia as an exemplar) to suggest that program effectiveness with primary self-sampling would be better than the current program, even if sensitivity is lower. Regulatory issues, suitable triage strategies, and clear communication about self-sampling are hurdles yet to be overcome. Nevertheless, existing evidence coupled with COVID-19 could be the tipping point for wider introduction of self-sampling.

Cite

CITATION STYLE

APA

Lim, A. W. W. (2021). Will COVID-19 be the tipping point for primary HPV self-sampling? Cancer Epidemiology Biomarkers and Prevention, 30(2), 245–247. https://doi.org/10.1158/1055-9965.EPI-20-1538

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free